Passively transferred lambert‐eaton syndrome in mice receiving purified IgG
- 1 August 1986
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 9 (6) , 523-530
- https://doi.org/10.1002/mus.880090608
Abstract
Purified IgG antibodies were prepared by ion‐exchange chromatography from the plasma of a patient with nonneoplastic form of the Lambert‐Eaton myasthenic syndrome (LES). The antibodies were injected into mice with daily doses of 0.15–10 mg for 20–22 days, following which the integrity of neuromuscular transmission was assessed in vitro in phrenic nerve‐diaphragm muscle preparations. The injected animals manifested electrophysiologic features of human LES, which were characterized by: (1) dose‐dependent reduction in the quantal content of nerve‐evoked endplate potentials, (2) an abnormally small increase in the frequency of spontaneous miniature endplate potentials (MEPPs) with elevated [K+]0, and (3) normal MEPP amplitude with no evidence of postjunctional deficiency. Crude immunoglobulins (Igs) from the same patient and two LES patients with associated malignancy similarly transferred the defects in quantal transmitter release. In contrast, animals receiving Igs from control subjects or from a patient with small‐cell carcinoma of the lung manifested no functional impairment of neuromuscular transmission. Instead, the evoked release in these animals was significantly enhanced relative to that found in normal untreated mice. These results suggest that an IgG antibody produces the presynaptic impairment that is characteristic of LES and support the concept that LES with and without cancer has an autoimmune pathogenesis.This publication has 14 references indexed in Scilit:
- Action of Lambert‐Eaton myasthenic syndrome IgG at mouse motor nerve terminalsAnnals of Neurology, 1985
- Passive transfer of the Lambert‐Eaton myasthenic syndrome: Neuromuscular transmission in mice injected with plasmaMuscle & Nerve, 1985
- Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones.Proceedings of the National Academy of Sciences, 1983
- Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse.The Journal of Physiology, 1983
- A computer system for real-time data acquisition and analysis of biopotentials and quantal content at the neuromuscular junctionComputer Programs in Biomedicine, 1983
- Paucity and disorganization of presynaptic membrane active zones in the lambert‐eaton myasthenic syndromeMuscle & Nerve, 1982
- AUTOIMMUNE AETIOLOGY FOR MYASTHENIC (EATON-LAMBERT) SYNDROMEThe Lancet, 1981
- On the release of transmitter at normal, myasthenia gravis and myasthenic syndrome affected human end‐plates.The Journal of Physiology, 1980
- A neuromuscular transmission block produced by a cancer tissue extract derived from a patient with the myasthenic syndromeNeurology, 1977
- QUANTAL COMPONENTS OF END‐PLATE POTENTIALS IN THE MYASTHENIC SYNDROME*Annals of the New York Academy of Sciences, 1971